NDAORALSUSPENSION
Approved
Aug 1949
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Triple Sulfas is a combination oral suspension of three sulfonamide antibiotics (sulfadiazine, sulfamerazine, and sulfamethazine) approved in 1949. The fixed-dose combination provides broad-spectrum antimicrobial coverage for bacterial infections. This product represents a legacy therapeutic approach with declining modern clinical use.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely small and focused on maintenance rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Triple Sulfas offers minimal career advancement given zero linked job openings and LOE-approaching lifecycle status. This role is suited only for professionals seeking stable, low-visibility maintenance positions rather than growth or innovation-focused career trajectories.
Brand ManagerSales Representative
Worked on TRIPLE SULFAS at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.